DK2514823T3 - Fremgangsmåder og sammensætninger til at behandle og detektere fejlfoldet SOD1-medierede sygdomme - Google Patents

Fremgangsmåder og sammensætninger til at behandle og detektere fejlfoldet SOD1-medierede sygdomme Download PDF

Info

Publication number
DK2514823T3
DK2514823T3 DK12161564.5T DK12161564T DK2514823T3 DK 2514823 T3 DK2514823 T3 DK 2514823T3 DK 12161564 T DK12161564 T DK 12161564T DK 2514823 T3 DK2514823 T3 DK 2514823T3
Authority
DK
Denmark
Prior art keywords
sod1
disease
antibody
seq
epitope
Prior art date
Application number
DK12161564.5T
Other languages
English (en)
Inventor
Neil Cashman
Avijit Chakrabartty
Rishi Rakhit
Joachim Bernhard Ostermann
Original Assignee
Promis Neurosciences Inc
Univ Health Network
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/367,609 external-priority patent/US7439324B2/en
Priority claimed from US11/565,967 external-priority patent/US7794692B2/en
Application filed by Promis Neurosciences Inc, Univ Health Network filed Critical Promis Neurosciences Inc
Application granted granted Critical
Publication of DK2514823T3 publication Critical patent/DK2514823T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0089—Oxidoreductases (1.) acting on superoxide as acceptor (1.15)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0312—Animal model for Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0318—Animal model for neurodegenerative disease, e.g. non- Alzheimer's
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/90283—Oxidoreductases (1.) acting on superoxide radicals as acceptor (1.15)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2828—Prion diseases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)

Claims (14)

  1. PAT E NT K RAV
    1. Sammensætning til anvendelse ved behandling af amyotrofisk lateral sklerose (ALS), hvor sammensætningen omfatter en farmaceutisk acceptabel vehikel og et middel valgt blandt: (1) et isoleret exogent antistof eller fragment deraf, der selektivt binder til en sygdomsspecifik epitop (DSE) valgt blandt i) DLGKGGNEESTKTGNAGS (SEQ ID NO:2) eller CDLGKGGNEESTKTGNAGS (SEQ ID NO: 11), ii) CIKGLTEGLHGF (SEQ ID NO:14) eller IKGLTEGLHGF (SEQ ID NO:5); og iii) GLHGFHVH (SEQ ID NO:7); og/eller iv) en sygdomsspecifik epitop af hvilken som helst af i), ii) eller iii), der omfatter en eller flere oxiderede eller nitrerede aminosyrer; og/eller (2) et immunogen, omfattende et peptid, der består af aminosyresekvensen af en hvilken som helst af SEQ ID NO: 2,5,7,11,14, hvor peptidet omfatter op til 50 SOD1-rester, eller et immunogen af (2), omfattende en eller flere oxiderede eller nitrerede aminosyrer.
  2. 2. Sammensætning til anvendelse ifølge krav 1, hvor antistoffet binder: i) DLGKGGNEESTKTGNAGS (SEQ ID NO:2) eller CDLGKGGNEESTKTGNAGS (SEQ ID NO: 11), ii) CIKGLTEGLHGF (SEQ ID NO:14) eller IKGLTEGLHGF (SEQ ID NO:5); eller iii) GLHGFHVH (SEQ ID NO:7).
  3. 3. Sammensætning til anvendelse ifølge krav 1 eller krav 2, hvor antistoffet binder: a) DLGKGGNEESTKTGNAGS (SEQ ID NO:2) eller CDLGKGGNEESTKTGNAGS (SEQ ID NO: 11); eller b) DLGKGGNEESTKTGNAGS (SEQ ID NO:2) eller CDLGKGGNEESTKTGNAGS (SEQ ID NO: 11), der omfatter en eller flere oxiderede eller nitrerede aminosyrer.
  4. 4. Sammensætning til anvendelse ifølge krav 1 eller krav 2, hvor antistoffet binder: a) GLHGFHVH (SEQ ID NO:7), IKGLTEGLHGF (SEQ ID NO:5) eller CIKGLTEGLHGF (SEQ ID NO:14); eller b) GLHGFHVH (SEQ ID NO:7), IKGLTEGLHGF (SEQ ID NO:5) eller CIKGLTEGLHGF (SEQ ID NO:14), der omfatter en eller flere oxiderede eller nitrerede aminosyrer.
  5. 5. Sammensætning til anvendelse ifølge et hvilket som helst af kravene 1 til 4, hvor midlet er et monoklonalt, polyklonalt, kimært eller humaniseret antistof.
  6. 6. Sammensætning til anvendelse ifølge et hvilket som helst af kravene 1 til 4, hvor midlet er immunogenet.
  7. 7. Sammensætning til anvendelse ifølge et hvilket som helst af kravene 1 til 6, hvor den amyotrofiske laterale sklerose (ALS) er sporadisk amyotrofisk lateral sklerose (sporadisk ALS).
  8. 8. Sammensætning til anvendelse ifølge et hvilket som helst af kravene 1, 4 eller 5, hvor DSE’en er modificeret ved oxidering.
  9. 9. Antistof eller en sammensætning, omfattende antistoffet, hvor antistoffet selektivt binder til en SOD1 -DSE valgt blandt: a) CIKGLTEGLHGF (SEQ ID NO:14), IKGLTEGLHGF (SEQ ID NO:5) eller GLHGFHVH (SEQ ID NO:7); eller b) CIKGLTEGLHGF (SEQ ID NO:14), IKGLTEGLHGF (SEQ ID NO:5) eller GLHGFHVH (SEQ ID NO:7), der omfatter en eller flere oxiderede eller nitrerede aminosyrer.
  10. 10. Immunogen, omfattende et isoleret peptid svarende til en SOD1-DSE valgt blandt: a) CIKGLTEGLHGF (SEQ ID NO:14), IKGLTEGLHGF (SEQ ID NO:5) eller GLHGFHVH (SEQ ID NO:7); eller b) CIKGLTEGLHGF (SEQ ID NO:14), IKGLTEGLHGF (SEQ ID NO:5) eller GLHGFHVH (SEQ ID NO:7), der omfatter en eller flere oxiderede eller nitrerede aminosyrer, hvor peptidet omfatter op til 50 SOD1 -rester.
  11. 11. Diagnostisk middel, omfattende (1) et antistof ifølge krav 9 bundet til (2) en markering, der producerer et detekterbart signal, direkte eller indirekte, hvor markeringen valgfrit omfatter en radioisotop, en fluorescerende forbindelse, en kemiluminescerende forbindelse, et enzym, et billeddannende middel eller en metalion.
  12. 12. Hybridoma betegnet 5C6, der er deponeret under accessionsnummer 280207-01 hos International Depositary Authority of Canada, eller hybridoma betegnet 3H1, der er deponeret under accessionsnummer 220207-02 hos International Depositary Authority of Canada.
  13. 13. Antistof produceret af hybridomaen ifølge krav 12.
  14. 14. Fremgangsmåde til opnåelse af et antistof ifølge krav 13, omfattende at dyrke hybridomaen og at isolere antistoffet.
DK12161564.5T 2006-03-03 2007-03-05 Fremgangsmåder og sammensætninger til at behandle og detektere fejlfoldet SOD1-medierede sygdomme DK2514823T3 (da)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US77837906P 2006-03-03 2006-03-03
US11/367,609 US7439324B2 (en) 2003-08-20 2006-03-03 ALS-specific peptide composition
US79872806P 2006-05-09 2006-05-09
US79872706P 2006-05-09 2006-05-09
US11/565,967 US7794692B2 (en) 2005-12-02 2006-12-01 Methods and compositions for detecting amyotrophic lateral sclerosis
EP07710682.1A EP1989308B1 (en) 2006-03-03 2007-03-05 Methods and compositions to treat and detect misfolded-sod1 mediated diseases

Publications (1)

Publication Number Publication Date
DK2514823T3 true DK2514823T3 (da) 2018-07-23

Family

ID=38460601

Family Applications (2)

Application Number Title Priority Date Filing Date
DK12161564.5T DK2514823T3 (da) 2006-03-03 2007-03-05 Fremgangsmåder og sammensætninger til at behandle og detektere fejlfoldet SOD1-medierede sygdomme
DK12161575.1T DK2495327T3 (da) 2006-03-03 2007-03-05 Fremgangsmåder og sammensætninger til at behandle og opdage sygdomme fremkaldt af fejlfoldet SOD1

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK12161575.1T DK2495327T3 (da) 2006-03-03 2007-03-05 Fremgangsmåder og sammensætninger til at behandle og opdage sygdomme fremkaldt af fejlfoldet SOD1

Country Status (7)

Country Link
US (4) US7977314B2 (da)
EP (5) EP2495327B1 (da)
JP (1) JP5823663B2 (da)
AU (1) AU2007219615B2 (da)
CA (1) CA2642848C (da)
DK (2) DK2514823T3 (da)
WO (1) WO2007098607A1 (da)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
EP1668369B1 (en) * 2003-08-20 2016-01-06 ProMIS Neurosciences Inc. Epitope protection assay and method for detecting protein conformations
US7962215B2 (en) 2004-07-23 2011-06-14 Synapse Biomedical, Inc. Ventilatory assist system and methods to improve respiratory function
US9050005B2 (en) 2005-08-25 2015-06-09 Synapse Biomedical, Inc. Method and apparatus for transgastric neurostimulation
BRPI0619249A2 (pt) 2005-11-30 2011-09-20 Abbott Lab anticorpos anti-globulÈmeros-aß, frações que se ligam a antìgeno destes, hibridomas correspondentes, ácidos nucléicos, vetores, células hospedeiras, métodos de produzir os ditos anticorpos, composições compreendendo os ditos anticorpos, usos dos ditos anticorpos e métodos de usar os ditos anticorpos
PT1976877E (pt) 2005-11-30 2014-04-29 Abbvie Inc Anticorpos monoclonais contra proteína beta-amilóide e suas utilizações
US7887803B2 (en) 2005-12-02 2011-02-15 Amorfix Life Sciences Methods and compositions to treat misfolded-SOD1 mediated diseases
US7794692B2 (en) * 2005-12-02 2010-09-14 Amorfix Life Sciences Ltd. Methods and compositions for detecting amyotrophic lateral sclerosis
DK2514823T3 (da) 2006-03-03 2018-07-23 Promis Neurosciences Inc Fremgangsmåder og sammensætninger til at behandle og detektere fejlfoldet SOD1-medierede sygdomme
ATE496987T1 (de) 2006-05-22 2011-02-15 Biovest Int Inc Ausserkapilläres fluidzirkulationssystem und - verfahren
US20080097153A1 (en) * 2006-08-24 2008-04-24 Ignagni Anthony R Method and apparatus for grasping an abdominal wall
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US9079016B2 (en) 2007-02-05 2015-07-14 Synapse Biomedical, Inc. Removable intramuscular electrode
EP2124952A2 (en) 2007-02-27 2009-12-02 Abbott GmbH & Co. KG Method for the treatment of amyloidoses
US9820671B2 (en) 2007-05-17 2017-11-21 Synapse Biomedical, Inc. Devices and methods for assessing motor point electromyogram as a biomarker
WO2009059033A1 (en) 2007-10-30 2009-05-07 Synapse Biomedical, Inc. Method of improving sleep disordered breathing
US8428726B2 (en) 2007-10-30 2013-04-23 Synapse Biomedical, Inc. Device and method of neuromodulation to effect a functionally restorative adaption of the neuromuscular system
US9217155B2 (en) 2008-05-28 2015-12-22 University Of Massachusetts Isolation of novel AAV'S and uses thereof
US20100233176A1 (en) * 2008-10-06 2010-09-16 Cashman Neil R Methods and systems for predicting misfolded protein epitopes
WO2010138263A2 (en) 2009-05-28 2010-12-02 University Of Massachusetts Novel aav 's and uses thereof
EP2512514B1 (en) * 2009-12-14 2014-11-05 Kyoto University Screening method for identifying compounds for treating amyotrophic lateral sclerosis
EP2558494B1 (en) 2010-04-15 2018-05-23 AbbVie Inc. Amyloid-beta binding proteins
US9272053B2 (en) 2010-04-23 2016-03-01 University Of Massachusetts AAV-based treatment of cholesterol-related disorders
EP3567106A1 (en) 2010-04-23 2019-11-13 University of Massachusetts Cns targeting aav vectors and methods of use thereof
CA2833905C (en) 2010-04-23 2019-09-10 University Of Massachusetts Multicistronic expression constructs
CN105348387B (zh) 2010-08-14 2020-08-25 Abbvie 公司 β淀粉样蛋白结合蛋白
AU2011320612A1 (en) 2010-10-26 2013-06-13 University Of Massachusetts Anti-SOD1 antibodies and uses thereof
US20120328605A1 (en) * 2010-10-27 2012-12-27 Daniel Larocque Compositions and uses
JP6067575B2 (ja) 2010-12-17 2017-01-25 ニューリミューン ホールディング エイジー ヒト抗ｓｏｄ１抗体
WO2012171030A2 (en) * 2011-06-10 2012-12-13 Biovest International, Inc. Method and apparatus for antibody production and purification
EP2909302A4 (en) 2012-08-28 2016-07-27 Biovest Int Inc BIOFABRICATION FILAMENT AND METHOD FOR LARGE-SCALE PRODUCTION OF CELLS, VIRUSES AND BIOMOLECULES
JP6490574B2 (ja) * 2013-02-28 2019-03-27 国立研究開発法人国立がん研究センター 不溶性フィブリンに対する抗体
GB2514407A (en) * 2013-05-23 2014-11-26 Stefan L Marklund Aggregates of superoxide dismutase
US9862777B2 (en) * 2013-05-28 2018-01-09 Vib Vzw Single domain antibodies against SOD1 and their use in medicine
CA3276269A1 (en) 2014-03-18 2026-03-02 University Of Massachusetts Raav-based compositions and methods for treating amyotrophic lateral sclerosis
US10975391B2 (en) 2014-04-25 2021-04-13 University Of Massachusetts Recombinant AAV vectors useful for reducing immunity against transgene products
WO2015187825A2 (en) 2014-06-03 2015-12-10 University Of Massachusetts Compositions and methods for modulating dysferlin expression
US10370432B2 (en) 2014-10-03 2019-08-06 University Of Massachusetts Heterologous targeting peptide grafted AAVS
RU2020140209A (ru) 2014-10-21 2021-01-25 Юниверсити Оф Массачусетс Варианты рекомбинантных aav и их применения
IL292999A (en) 2014-11-14 2022-07-01 Voyager Therapeutics Inc Compositions and methods of treating amyotrophic lateral sclerosis (als)
US10633433B2 (en) 2015-01-28 2020-04-28 Prothena Biosciences Limited Anti-transthyretin antibodies
US10464999B2 (en) 2015-01-28 2019-11-05 Prothena Biosciences Limited Anti-transthyretin antibodies
US9879080B2 (en) 2015-01-28 2018-01-30 Prothena Biosciences Limited Anti-transthyretin antibodies
WO2016131009A1 (en) 2015-02-13 2016-08-18 University Of Massachusetts Compositions and methods for transient delivery of nucleases
US11046955B2 (en) 2015-04-24 2021-06-29 University Of Massachusetts Modified AAV constructs and uses thereof
EP3397344A4 (en) * 2015-12-28 2019-08-28 B.G. Negev Technologies and Applications Ltd. at Ben-Gurion University COMPOSITION AND METHOD FOR THE TREATMENT OF AMYOTROPHER LATERAL SCLEROSIS
WO2017136536A1 (en) 2016-02-02 2017-08-10 University Of Massachusetts Method to enhance the efficiency of systemic aav gene delivery to the central nervous system
WO2017139643A1 (en) 2016-02-12 2017-08-17 University Of Massachusetts Anti-angiogenic mirna therapeutics for inhibiting corneal neovascularization
CA3026103A1 (en) * 2016-06-10 2017-12-14 Saunders, Ann M. Methods for detecting structural variants in neurodegenerative disease
US10457940B2 (en) 2016-09-22 2019-10-29 University Of Massachusetts AAV treatment of Huntington's disease
CA3040483A1 (en) 2016-10-13 2018-04-19 University Of Massachusetts Aav capsid designs
SG11201909870SA (en) 2017-05-05 2019-11-28 Voyager Therapeutics Inc Compositions and methods of treating amyotrophic lateral sclerosis (als)
EP3622073A4 (en) 2017-05-09 2021-01-06 University of Massachusetts METHOD FOR TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
EP3658172A4 (en) 2017-07-25 2021-05-05 TrueBinding, Inc. TREATING CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND HIS LIGAND
US11739330B2 (en) 2017-09-22 2023-08-29 University Of Massachusetts SOD1 dual expression vectors and uses thereof
PE20210042A1 (es) 2017-10-06 2021-01-08 Prothena Biosciences Ltd Metodos para detectar transtiretina
CN111315213B (zh) 2017-10-06 2023-09-12 普罗塞纳生物科学有限公司 抗甲状腺素运载蛋白抗体
EP4454654A3 (en) 2017-10-16 2025-02-19 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (als)
US11434502B2 (en) 2017-10-16 2022-09-06 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (ALS)
EA202091012A1 (ru) 2017-10-25 2020-08-27 Янссен Фармасьютикалз, Инк. Композиции фосфорилированных тау-пептидов и их применения
AU2018375356A1 (en) 2017-11-29 2020-05-14 Neotope Neuroscience Limited Lyophilized formulation of a monoclonal antibody against transthyretin
US12163129B2 (en) 2018-06-08 2024-12-10 University Of Massachusetts Antisense oligonucleotides to restore dysferlin protein expression in dysferlinopathy patient cells
CA3103963A1 (en) 2018-07-02 2020-01-09 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis and disorders associated with the spinal cord
CN112584863B (zh) * 2018-08-17 2025-10-28 Ab工作室有限公司 催化抗体和其使用方法
US11471683B2 (en) 2019-01-29 2022-10-18 Synapse Biomedical, Inc. Systems and methods for treating sleep apnea using neuromodulation
CN113711036B (zh) 2019-01-30 2025-03-18 真和制药有限公司 抗gal3抗体及其用途
CN113710269A (zh) 2019-02-08 2021-11-26 Ac免疫有限公司 磷酸化Tau肽疫苗的安全施用方法
EP4121766A1 (en) * 2020-03-18 2023-01-25 AL-S Pharma AG Misfolded sod1 assay
CN116157151A (zh) 2020-05-26 2023-05-23 真和制药有限公司 通过阻断半乳凝素-3治疗炎性疾病的方法
JP7376203B2 (ja) * 2021-08-18 2023-11-08 株式会社 バイオラジカル研究所 身体的フレイルの試験方法、身体的フレイルの試験試薬、身体的フレイルの治療薬候補物質のスクリーニング方法、精神的フレイルの試験方法、精神的フレイルの試験試薬、および精神的フレイルの治療薬候補物質のスクリーニング方法
JPWO2023033050A1 (da) * 2021-09-02 2023-03-09
TW202449167A (zh) 2023-04-26 2024-12-16 美商航海家醫療公司 用於治療肌肉萎縮性脊髓側索硬化症之組成物及方法

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4910133A (en) * 1985-08-29 1990-03-20 Ube Industries, Limited Diagnostic test drug comprising monoclonal antibody to human copper.zinc-superoxide dismutase and diagnostic test method using the same
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4940659A (en) 1987-02-20 1990-07-10 Monoclonetics International, Inc. Screening extra-cellular body fluids for superoxide dismutase (SOD-1) for determining fetal trisomy 21 down syndrome
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
US4806627A (en) * 1987-05-29 1989-02-21 Research Foundation Of Mental Hygiene Inc. Hybrid cell lines producing monoclonal antibodies dircted against scrapie-associated fibril proteins
US5672344A (en) 1987-12-30 1997-09-30 The Regents Of The University Of Michigan Viral-mediated gene transfer system
AU2894889A (en) 1988-02-01 1989-08-03 Monoclonetics International Incorporated Genetic markers for down's syndrome, fetal abnormalities and twins
GB8911525D0 (en) 1989-05-19 1989-07-05 Allied Colloids Ltd Polymeric composition
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5240846A (en) 1989-08-22 1993-08-31 The Regents Of The University Of Michigan Gene therapy vector for cystic fibrosis
US5436146A (en) 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
ES2284161T3 (es) 1990-01-12 2007-11-01 Amgen Fremont Inc. Generacion de anticuerpos xenogenicos.
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5670488A (en) 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5529774A (en) 1991-08-13 1996-06-25 The Regents Of The University Of California In vivo transfer of the HSV-TK gene implanted retroviral producer cells
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
NZ244306A (en) 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
US5911983A (en) 1992-06-26 1999-06-15 University Of Pittsburgh Gene therapy for Gaucher disease using retroviral vectors
US5843641A (en) * 1993-02-26 1998-12-01 Massachusetts Institute Of Technology Methods for the daignosis, of familial amyotrophic lateral sclerosis
ATE301201T1 (de) 1993-06-07 2005-08-15 Vical Inc Für die gentherapie verwendbare plasmide
US5645829A (en) 1993-06-18 1997-07-08 Beth Israel Hospital Association Mesothelial cell gene therapy
US5562909A (en) 1993-07-12 1996-10-08 Massachusetts Institute Of Technology Phosphazene polyelectrolytes as immunoadjuvants
GB9326174D0 (en) 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
US5656465A (en) 1994-05-04 1997-08-12 Therion Biologics Corporation Methods of in vivo gene delivery
US5714353A (en) 1994-05-24 1998-02-03 Research Corporation Technologies, Inc. Safe vectors for gene therapy
US20030072774A1 (en) 1994-06-10 2003-04-17 Diane M. Gajewczyk Proteinaceous adjuvants
US5639642A (en) 1994-06-16 1997-06-17 Novo Nordisk A/S Synthetic leader peptide sequences
GB9506466D0 (en) 1994-08-26 1995-05-17 Prolifix Ltd Cell cycle regulated repressor and dna element
US6019982A (en) 1994-08-26 2000-02-01 The Administrators Of The Tulane Educational Fund Mutant enterotoxin effective as a non-toxic oral adjuvant
DE19524720A1 (de) 1995-07-12 1997-01-16 Hoechst Ag Zellspezifische Gentherapie mit Hilfe eines neuen Promotors für den "Tissue Inhibitor of Metalloproteinasn-3"
JP4216350B2 (ja) 1994-09-19 2009-01-28 大日本住友製薬株式会社 動物細胞感染用の組換えｄｎａウイルスベクター
FR2726764B1 (fr) 1994-11-14 1997-01-31 Pasteur Merieux Serums Vacc Adjuvant pour composition vaccinale
US5789147A (en) 1994-12-05 1998-08-04 New York Blood Center, Inc. Method for concentrating white cells from whole blood by adding a red cell sedimentation reagent to whole anticoagulated blood
US5869040A (en) 1995-06-07 1999-02-09 Biogen, Inc Gene therapy methods and compositions
US6743771B2 (en) 1995-12-29 2004-06-01 Novactyl, Inc. Methods and compositions for controlling protein assembly or aggregation
US5834457A (en) * 1996-01-26 1998-11-10 The Regents Of The University Of California Method of modulating radical formation by mutant cuznsod enzymes
US6270954B1 (en) * 1996-04-10 2001-08-07 The Regents Of The University Of California Correction of genetic defects using chemical chaperones
US5735814A (en) 1996-04-30 1998-04-07 Medtronic, Inc. Techniques of treating neurodegenerative disorders by brain infusion
US5928914A (en) 1996-06-14 1999-07-27 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Methods and compositions for transforming cells
EP0861900A1 (en) * 1997-02-21 1998-09-02 Erziehungsdirektion Of The Canton Zurich Immunological detection of prions
WO1998046273A2 (en) 1997-04-17 1998-10-22 Paola Leone Delivery system for gene therapy to the brain
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
US7157098B1 (en) 1998-01-06 2007-01-02 Roman Perez-Soler Gene therapy of tumors using non-viral delivery system
US6214565B1 (en) * 1998-10-09 2001-04-10 The Regents Of The University Of California Assay for disease related conformation of a protein and isolating same
WO1999061066A2 (en) 1998-05-27 1999-12-02 Avigen, Inc. Convection-enhanced delivery of aav vectors
GB9818756D0 (en) 1998-08-27 1998-10-21 Microbiological Research Agenc Superoxide dismutase as a vaccine antigen
AU6234099A (en) 1998-10-16 2000-05-08 Introgene B.V. Gene therapy of alzheimer's disease by delivery of an encoded apoliprotein
US7012061B1 (en) 1998-10-19 2006-03-14 New York University Method for increasing the permeability of the blood brain barrier
US7041807B1 (en) * 1999-06-23 2006-05-09 Caprion Pharmaceuticals, Inc. Antibodies to a YYX epitope of a mammalian prion protein
MXPA01013186A (es) 1999-06-23 2002-08-12 Caprion Pharmaceuticals Inc Peptidos de la proteina prion y sus usos.
WO2001006989A2 (en) 1999-07-27 2001-02-01 Abgenix, Inc. Methods and compositions for inhibiting polypeptide accumulation associated with neurological disorders
EP1132098B1 (en) 1999-09-21 2010-05-26 AnGes MG, Inc. Gene therapy for cerebrovascular disorders
SK287694B6 (sk) 2000-06-15 2011-06-06 Novartis Vaccines & Diagnostics, Inc. Pevný nosič imunoeseje a spôsob jeho prípravy, spôsob detekcie infekcie HIV a súprava na imunodiagnostickú skúšku
DE60234163D1 (de) 2001-01-05 2009-12-10 Viromed Ltd Zusammensetzungen zur gentherapie rheumatoider arthritis, die ein gen, das für ein anti-angiogenes protein oder teile davon kodiert, enthalten
US20030022243A1 (en) * 2001-06-20 2003-01-30 Les Kondejewski Protein aggregation assays and uses thereof
DE10152677A1 (de) 2001-10-19 2003-05-08 Aventis Behring Gmbh Antikörper zum spezifischen Nachweis von pathogenen Prionen humanen Ursprungs und damit durchgeführten Nachweisverfahren
US7763591B2 (en) 2001-11-28 2010-07-27 Anges Mg, Inc. Hepatocyte growth factor gene therapy for parkinson's disease
US7141044B2 (en) 2001-12-11 2006-11-28 Ekos Corporation Alternate site gene therapy
AU2002950217A0 (en) 2002-07-16 2002-09-12 Prana Biotechnology Limited 8- Hydroxy Quinoline Derivatives
ATE506072T1 (de) 2002-09-12 2011-05-15 Univ California Immunogene und entsprechende antikörper, die spezifisch sind für häufige hochmolekulare aggregations-zwischenprodukte von amyloiden aus proteinen unterschiedlicher sequenz
AU2003266801B2 (en) 2002-12-19 2010-02-25 Ortho-Clinical Diagnostics, Inc Detection and diagnosis of transmissable spongiform encephalopathies
WO2004091398A2 (en) 2003-04-15 2004-10-28 Philips Intellectual Property & Standards Gmbh Method and apparatus for improved determination of spatial non-agglomerated magnetic particle distribution in an area of examination
CA2437999C (en) 2003-08-20 2013-10-08 Neil Cashman Epitope protection assay
EP1668369B1 (en) * 2003-08-20 2016-01-06 ProMIS Neurosciences Inc. Epitope protection assay and method for detecting protein conformations
CA2437675A1 (en) 2003-08-20 2005-02-20 Neil Cashman Methods of detecting prion protein
CA2536305C (en) 2003-08-20 2015-10-27 Amorfix Life Sciences Ltd. Sod-1 epitopes and antibodies
WO2005024042A2 (en) 2003-09-04 2005-03-17 The Regents Of The University Of California Aptamers and methods for their in vitro selection and uses thereof
WO2005077040A2 (en) 2004-02-11 2005-08-25 Rensselaer Polytechnic Institute Compositions and methods for treating amyotrophic lateral sclerosis (als)
US20060073119A1 (en) 2004-09-01 2006-04-06 Avigen, Inc. Methods for treating neurodegenerative disorders
US20060122116A1 (en) 2004-11-03 2006-06-08 The Johns Hopkins University Treatment for disorders of the peripheral nervous system
US20060129126A1 (en) 2004-11-19 2006-06-15 Kaplitt Michael G Infusion device and method for infusing material into the brain of a patient
WO2006091403A2 (en) * 2005-02-18 2006-08-31 The Cleveland Clinic Foundation Systemic markers for asthma and analogous diseases
US20060194821A1 (en) 2005-02-18 2006-08-31 The Brigham And Women's Hospital, Inc. Compounds inhibiting the aggregation of superoxide dismutase-1
EP1937827B1 (en) * 2005-08-31 2011-09-28 Université Laval Antibodies and their use in the treatment, prevention and diagnosis of a disease associated with sod1 abnormalities
US7887803B2 (en) 2005-12-02 2011-02-15 Amorfix Life Sciences Methods and compositions to treat misfolded-SOD1 mediated diseases
US7794692B2 (en) 2005-12-02 2010-09-14 Amorfix Life Sciences Ltd. Methods and compositions for detecting amyotrophic lateral sclerosis
WO2007067900A2 (en) 2005-12-05 2007-06-14 Prosetta Corporation Biomarkers for amyotrophic lateral sclerosis
DK2514823T3 (da) 2006-03-03 2018-07-23 Promis Neurosciences Inc Fremgangsmåder og sammensætninger til at behandle og detektere fejlfoldet SOD1-medierede sygdomme
CN201029168Y (zh) 2007-03-09 2008-02-27 富士康(昆山)电脑接插件有限公司 电连接器
JP4701420B2 (ja) 2007-07-31 2011-06-15 タイヨーエレック株式会社 弾球遊技機
WO2010003227A1 (en) 2008-07-08 2010-01-14 Amorfix Life Sciences Ltd. Detection of protein aggregates
FR2933686B1 (fr) 2008-07-09 2010-11-19 Saint Gobain Emballage Composition de renforcement du verre creux et de protection de celui-ci contre la rayure, procedes de traitement correspondants et verre creux traite obtenu
US20100233176A1 (en) 2008-10-06 2010-09-16 Cashman Neil R Methods and systems for predicting misfolded protein epitopes
JP2010153006A (ja) 2008-12-26 2010-07-08 Konica Minolta Opto Inc 対物光学素子及び光ピックアップ装置
CA2753621A1 (en) 2009-03-02 2010-09-10 The University Of British Columbia Antibodies and epitopes specific to misfolded prion protein
CA3233345A1 (en) 2012-04-09 2013-10-17 Case Western Reserve University Compositions and methods for inhibiting the activity of lar family phosphatases
JP6430373B2 (ja) 2012-06-12 2018-11-28 プロミス、ニューロサイエンシズ、インコーポレイテッドＰｒｏｍｉｓ Ｎｅｕｒｏｓｃｉｅｎｃｅｓ Ｉｎｃ． ミスフォールドプリオンタンパク質を標的とする抗体および複合体
US9902442B2 (en) 2015-04-06 2018-02-27 John P. Moyna Track link

Also Published As

Publication number Publication date
DK2495327T3 (da) 2017-01-02
EP2514824A2 (en) 2012-10-24
EP2502999A3 (en) 2013-01-23
EP1989308A1 (en) 2008-11-12
WO2007098607A1 (en) 2007-09-07
US20180079825A1 (en) 2018-03-22
US9637552B2 (en) 2017-05-02
US20070292410A1 (en) 2007-12-20
WO2007098607A8 (en) 2016-10-27
AU2007219615B2 (en) 2013-11-28
EP1989308B1 (en) 2017-05-31
AU2007219615A1 (en) 2007-09-07
EP2514823A3 (en) 2013-01-23
EP2495327A3 (en) 2012-10-17
EP2514823B1 (en) 2018-05-02
CA2642848C (en) 2016-07-12
US20110305701A1 (en) 2011-12-15
EP2514824A3 (en) 2013-01-23
EP2514823A2 (en) 2012-10-24
JP5823663B2 (ja) 2015-11-25
EP1989308A4 (en) 2009-12-30
JP2009529498A (ja) 2009-08-20
US20140348822A1 (en) 2014-11-27
CA2642848A1 (en) 2007-09-07
EP2502999A2 (en) 2012-09-26
EP2495327A2 (en) 2012-09-05
EP2495327B1 (en) 2016-09-28
US7977314B2 (en) 2011-07-12
US8778885B2 (en) 2014-07-15

Similar Documents

Publication Publication Date Title
EP2514823B1 (en) Methods and compositions to treat and detect misfolded-SOD1 mediated diseases
US8709422B2 (en) Methods and compositions to treat and detect misfolded-SOD1 mediated diseases
JP6174667B2 (ja) 病理学的タウタンパク質の免疫学的標的化方法
KR101831459B1 (ko) 올리고머 특이적 아밀로이드 베타 에피토프 및 항체
US9834582B2 (en) Immunotherapy targeting of the shared abnormal conformational state of amyloidogenic peptides/proteins
JP7204235B2 (ja) 活性型α－シヌクレインに結合する抗体
Tan et al. Development of an anti-tauopathy mucosal vaccine specifically targeting pathologic conformers
DK1989308T3 (da) Fremgangsmåder og sammensætninger til at behandle og detektere fejlfoldet SOD1-medierede sygdomme
HK1175500B (en) Methods and compositions to treat and detect misfolded-sod1 mediated diseases
HK1124885B (en) Methods and compositions to treat and detect misfolded-sod1 mediated diseases
HK1124885A (en) Methods and compositions to treat and detect misfolded-sod1 mediated diseases
HK1176378A (en) Methods and compositions to treat and detect misfolded-sod1 mediated diseases
HK1175500A (en) Methods and compositions to treat and detect misfolded-sod1 mediated diseases
HK1175501A (en) Methods and compositions to treat and detect misfolded-sod1 mediated diseases
HK1175810A (en) Methods and compositions to treat and detect misfolded-sod1 mediated diseases